Ebola could be transformed from a terrifying disease into something that can be managed at home if drug trials in the Democratic Republic of the Congo are successful, a leading scientist believes.
Ebola virus can persist in immunologically protected body sites in survivors of Ebola virus disease, creating the potential to initiate new chains of transmission.
This toolkit is intended for use by hospital emergency departments, and tests how long it takes for a potential patient with a highly infectious disease to be identified and for staff to begin exposure mitigation procedures; how long it takes for a patient to be transferred to an isolation room; and the capability of the facility to make notifications internally and to the health department.
Researchers have discovered that certain derivatives of amodiaquine, a medication typically used to treat malaria, could provide a new therapeutic approach to treating patients infected with Ebola virus disease by blocking the viruses from entering cells.
For more than 40 years, the British Royal Air Force has maintained an aeromedical evacuation facility, the Deployable Air Isolator Team (DAIT), to transport patients with possible or confirmed highly infectious diseases to the United Kingdom. Currently, no UK-published guidelines exist on how to transfer such patients.
To evaluate the effect of health care worker(HCW) targeted or community vaccination strategies, researchers used a transmission model to explore the relative contribution of HCW and the community to transmission.
Scientists have successfully engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models. DMAbs may also provide a novel powerful platform for rapid screening of monoclonal antibodies enhancing preclinical development.
Health officials are preparing to launch a clinical trial designed to test whether experimental Ebola therapies improve patients’ chances of survival in the outbreak in the Democratic Republic of the Congo.
The US Food and Drug Administration (FDA) announced that an emergency use authorization (EUA) has been issued for a rapid, single-use test for the detection of Ebola virus (Zaire ebolavirus). This is the second Ebola rapid antigen fingerstick test available under EUA, but the first that uses a portable battery-operated reader, which can help provide clear diagnostic results outside of laboratories.
Uganda will become the first country in the world to give the vaccine against Ebola without experiencing an active outbreak.